Hope for rare eye disease: experimental gene therapy offered to control group
Disease control
ENROLLING_BY_INVITATION
This study provides the ZVS101e injection to 32 people with Bietti crystalline corneoretinal dystrophy who were previously in a control group. The goal is to offer treatment and check for side effects. Participants must have completed a 52-week follow-up in an earlier phase 3 tri…
Phase: NA • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC